Frontline Bemarituzumab Doublet Prolongs Survival in Advanced FGFR2b+ Gastric/GEJ Cancer
January 16th 2021In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.
Neratinib Plus Capecitabine Improved PFS in Patients With HER2+ Breast Cancer With Brain Mets
December 15th 2020Neratinib in combination with capecitabine induced a 34% reduction in the risk of disease progression or death as treatment of patients with HER2-positive breast cancer who had central nervous system metastases at baseline compared with lapatinib and capecitabine.
GP2/GM-CSF Combination Induces 100% Disease-Free Survival Rate at 5 years in HER2 3+ Breast Cancer
December 11th 2020The GP2 immunotherapy in combination with granulocyte-macrophage colony-stimulating factor induced a 100% disease-free survival with potent responses as treatment of patients with HER2/neu 3–positive disease who received adjuvant trastuzumab .
Oral Paclitaxel Combination Reduces the Risk of Death in Patients With mBC
December 9th 2020In the phase 3 KX-ORAX-001 clinical trial, treatment with paclitaxel in combination with encequidar achieved a 26.5% reduction in the risk of death compared with paclitaxel by intravenous injection in patients with metastatic breast cancer.
Significant Responses Seen With Investigational BTK Inhibitor in Pretreated CLL/SLL Population
December 8th 2020A high objective response rate was observed in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with LOXO-305, according to results of the phase 1/2 BRUIN trial presented during the 2020 ASH Annual Meeting.
Mosunetuzumab Elicits High and Durable Responses in Subgroups of Patients With FL
December 8th 2020A phase clinical trial has demonstrated that administering a mosunetuzumab fixed-duration leads to high, durable, and consistent responses in patients with follicular lymphoma across multiple subgroups. Data from the study were presented during the virtual 2020 American Society of Hematology Annual Meeting.
Odronextamab Shows Intriguing Antitumor Activity in Relapsed/Refractory B-Cell NHL
December 6th 2020Promising antitumor activity, as well as an acceptable safety profile, continues to be demonstrated with odronextamab, a novel CD20xCD3 bispecific antibody, as treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Kaelin Speaks to the Future of I/O, HIF-2α, CDK4/6 Inhibitors in VHL Disease–Associated RCC
November 7th 2020During a keynote address for the International Kidney Cancer Symposium, William G. Kaelin Jr, MD, spoke of recent research on effective treatment with the ability to target von Hippel-Lindau disease–associated renal cell carcinoma. These drugs included immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors, which may be the future of the treatment paradigm.
Selecting I/O or Targeted Therapy as Adjuvant Treatment of BRAF-Mutant Melanoma
November 5th 2020During a virtual presentation for the 38th Annual Chemotherapy Foundation Symposium, Janice M. Mehnert, MD explained the science behind selecting the optimal adjuvant therapy for patients with BRAF-mutant melanoma. The options Mehnert weighed were immunotherapy and BRAF-targeted therapy.
Tisotumab Vedotin Shows Promise in Recurrent/Metastatic Cervical Cancer
September 21st 2020In the phase 2 single-arm innovaTV 204 trial, treatment with tisotumab vedotin led to an objective response rate (ORR) of 24% (95% CI, 15.9%-33.3%) in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab (Avastin). The encouraging result was announced during a presentation at the 2020 European Society of Medical Oncology (ESMO) Virtual Congress.
Ipatasertinib Combo Prolongs PFS in PTEN-Loss mCRPC
September 21st 2020A primary analysis from the phase 3 IPATential150 trial demonstrated the benefit of the addition of ipatasertib to abiraterone acetate and prednisone in the treatment of patients with metastatic castration-resistant prostate cancer with PTEN loss, according to results presented at the 2020 ESMO Virtual Congress.
BLU-945 Shows Early Antitumor Activity in EGFR-Mutated NSCLC Models
September 20th 2020In preclinical models of triple-mutated EGFR-positive non–small cell lung cancer, the investigational agent, BLU-945 induced robust antitumor responses, according to results presented at the 2020 European Society of Medical Oncology Virtual Congress.
Frontline Lorlatinib Leads to Better Outcomes Compared With Crizotinib in Advanced ALK+ NSCLC
September 20th 2020According to results from the phase 3 CROWN trial, the third-generation ALK tyrosine kinase inhibitor loralitinib achieved a significant improvement in progression-free survival as well as higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.
Activity Observed With Balstilimab With or Without Zalifrelimab for Cervical Cancer
September 19th 2020In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status, plus a tolerable safety profile, according to data from 2 independent phase 2 trials presented during the 2020 ESMO Virtual Congress.
Survival Improved With Frontline Avelumab as Maintenance in Advanced Urothelial Carcinoma
September 19th 2020Avelumab in combination with best supportive care as frontline maintenance in patients with advanced or metastatic urothelial carcinoma who had not progressed on first-line platinum-based chemotherapy led to improvements in both progression-free and overall survival.